TICKERNERD
Menu
JAGXJAGXHealthcare · Biotechnology

JAGX Stock Forecast: Jaguar Health, Inc. Price Predictions for 2026-2027

Last close, 1 Oct 2026
$3.95

The 1 Wall Street analysts covering Jaguar Health, Inc. hold a median 12-month price target of $263 — +6545.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 1 Oct 2026 — in the upper half.

Market cap
$2.1M
Ticker Nerd rank
62 / 100
Median analyst target
$263
Analysts covering
1
Revenue$1.2M−58.9% y/y
Operating income−$7.6M
Net income−$12.8M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

JAGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jaguar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Oct 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Growth
96
Size
94
Quality
53
Issuance
52
Value
48
Revisions
25
Momentum
25
Volatility
8

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JAGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JAGX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $263Median $263High $263

The green dot is the last close — the median target sits +6545.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2025First BerlinInitiatesBuy$60
7 July 2021Cantor FitzgeraldInitiatesOverweight$5.00
25 Nov 2020Aegis CapitalInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
25 Nov 2020Rodman & RenshawInitiatesBuy—
18 Nov 2019H.C. WainwrightReiteratesBuy—
18 Nov 2019HC Wainwright & Co.ReiteratesBuy$10 → $3.00
12 Sept 2019Ladenburg ThalmannInitiatesBuy—
11 July 2017Rodman & RenshawInitiatesBuy—
12 Nov 2015Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JAGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

JAGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Jaguar Health, Inc. (JAGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
0.1×

Cheaper than 97% of US stocks

Price / book
2.9×

Cheaper than 32% of US stocks

EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−58.9%

Higher than 4% of US stocks

Earnings growth (YoY)
−58.9%

Higher than 9% of US stocks

Gross margin
15.8%

Higher than 15% of US stocks

Operating margin
−620.2%

Higher than 7% of US stocks

Net margin
−130.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−548.8%

Higher than 3% of US stocks

Return on assets
−38.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jaguar Health, Inc. (JAGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jaguar Health, Inc. has a market value of $2.1M and an enterprise value of $14.4M.

  • Revenue in the twelve months to 30 June 2026: $27.8M. The latest quarter shrank 58.9% year on year.

  • Net income over the same four quarters: −$36.9M, a −132.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.7M.

  • Shares outstanding: 4.9M.

  • Trailing P/E: 0.0×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Jaguar Health, Inc. employs 47 people — $591K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Oct 2026

Data provided by Twelve Data

Peers

JAGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JAGXJaguar Health, Inc.$2.1M
62
NRSNNeurosense Therapeutics Ltd.$7.7M
3
CNSPCNS Pharmaceuticals, Inc.$7.7M
23
ENSCEnsysce Biosciences, Inc.$7.8M
38
AZTRAzitra, Inc.$7.8M
40
CURXCuranex Pharmaceuticals, Inc.$7.8M
6
KALAKala Bio, Inc.$7.8M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jaguar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JAGX news & analysis

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Accesswire · 29 Sept 2026positive

Jaguar Health's Napo Pharmaceuticals announced that an abstract on preliminary results from an ongoing open-label study of crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) was accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026), taking place October 9-14, 2026 in Nashville. The company remains focused on its rare disease intestinal failure development program for crofelemer, targeting an NDA filing for microvillus inclusion disease (MVID) in mid-2027.

Why it matters — This presentation highlights progress in Jaguar's rare disease development program for crofelemer in intestinal failure conditions, which may be of interest to JAGX watchers tracking the company's pipeline milestones.

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

24/7 Wall Street · 25 Sept 2026positive

Jaguar Health shares rose 32% to $9.32 in morning trading following a rare-disease pipeline update and a thin post-split float. The surge was attributed to company-specific factors.

Why it matters — JAGX watchers would note the stock's sharp move driven by pipeline news and the reduced share float after the split.

Jaguar Health Stock Surges Friday: What's Happening?

Benzinga · 25 Sept 2026positive

Jaguar Health shares rose on Friday morning, recovering from the prior session's dilution-related decline after the company announced additional debt-for-equity exchanges that cut its outstanding debt by over $6.7 million and retired a major promissory note.

Why it matters — A JAGX watcher would care because the debt reduction and retirement of a major promissory note represent a strengthening of the company's balance sheet.

Jaguar Health Stock Slides Thursday: What's Happening?

Benzinga · 24 Sept 2026negative

Jaguar Health Inc. shares fell Thursday afternoon as equity dilution concerns weighed on the micro-cap biopharmaceutical company following a debt-for-equity exchange.

Why it matters — JAGX watchers would care because the debt-for-equity exchange raises dilution concerns that are pressuring the stock.

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

24/7 Wall Street · 24 Sept 2026negative

Thursday morning saw Jaguar Health's stock tumble 25% while the broader biotech sector benchmark edged higher. The move was company-specific rather than driven by sector-wide rotation, with the decline occurring as rival Viking Therapeutics also fell sharply after pricing a $500M offering.

Why it matters — Jaguar Health watchers would note that the stock's sharp decline on this trading day points to company-specific pressures rather than broader sector headwinds.

FAQ

Frequently asked questions about JAGX stock

What is the JAGX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Jaguar Health, Inc. have a median 12-month price target of $263, with estimates ranging from $263 to $263. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JAGX stock a buy right now?

Of the 1 analysts covering Jaguar Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jaguar Health, Inc. 62 out of 100 across roughly 4,600 US stocks as at 1 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JAGX?

As at 1 Oct 2026, Jaguar Health, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will JAGX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +6545.6% from the last close, and Ticker Nerd's factor model ranks Jaguar Health, Inc. 62 out of 100 as at 1 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JAGX stock forecast for 2030?

No analyst covering Jaguar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $263 to $263 over the next 12 months.

What does Jaguar Health, Inc. do?

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals.

What is the latest news on JAGX?

The most recent item we track (Accesswire, 29 Sept 2026): "Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting". Jaguar Health's Napo Pharmaceuticals announced that an abstract on preliminary results from an ongoing open-label study of crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) was accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026), taking place October 9-14, 2026 in Nashville. The company remains focused on its rare disease intestinal failure development program for crofelemer, targeting an NDA filing for microvillus inclusion disease (MVID) in mid-2027.

Company

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.

CEO Ms. Lisa A. Conte · 47 employees · United States · https://jaguar.health